Semax is not a classical stimulant. It is a dedicated cognitive accelerator — a heptapeptide analogue of ACTH 4-7 (Met-Glu-His-Phe-Pro-Gly-Pro) that acutely upregulates BDNF, NGF and dopamine D2/D3 without catecholamine side-effects. Russian neuroprotective heritage, focus without rebound.
The biochemical foundation — a heptapeptide fragment of ACTH with neurotrophic focus
In the peptide research field, cognitive research compounds are typically dominated by catecholamine modulators (amphetamine analogues, modafinil-references) — and these carry one inevitable burden: dopamine receptor downregulation, cardiovascular pressure and acute crash-circuits.
Semax breaks that paradigm. Instead of directly releasing dopamine, it acutely upregulates BDNF and NGF and activates dopamine D2/D3 receptors via a non-stimulant signaling pathway. The result in in-vitro and preclinical models: measurable acute focus without catecholamine peak, without receptor downregulation, and without the typical post-stimulant crash.
Semax (Met-Glu-His-Phe-Pro-Gly-Pro, MW: 813.94 g/mol) is a synthetic heptapeptide derived from the ACTH 4-7 fragment (Met-Glu-His-Phe), extended with a Pro-Gly-Pro tail for enzymatic stability and blood-brain barrier penetration via intranasal or parenteral research exposure.
"Amphetamines borrow tomorrow's dopamine. Semax invests in today's BDNF."
In that respect, Semax is fundamentally different from classical "nootropic research compounds" — it does not act as a monoamine reuptake inhibitor, not as a catecholamine releaser, and not as an acetylcholinesterase inhibitor. It operates upstream at the level of neurotrophic factor expression and synaptic plasticity — a more fundamental neuroprotective position in the central nervous system.
What does Semax do razor-sharp differently?
Semax (MEHFPGP, MW: 813.94 g/mol) operates on multiple layers simultaneously:
- Acute BDNF upregulation in hippocampus and frontal cortex → measurable within 30-60 min in animal models
- NGF (Nerve Growth Factor) expression upregulated → synaptic density enhanced in chronic exposure
- Acute dopamine D2/D3 receptor activation without catecholamine release → focus without amphetamine peak
- Enkephalin-degrading peptidase inhibition → endogenous opioid tone stabilisation
- Selective serotonin modulation in prefrontal cortex → attention and working memory support
- Neuroprotective response in ischaemic research models (stroke, cerebral hypoxia) — documented in Russian clinical research
- Anti-inflammatory response in microglia (reduced TNF-α, IL-6) — chronic neuro-inflammation models
Semax vs Selank — Side-by-Side
| Property | Semax (Cognitive Activation) | Selank (Cognitive Homeostasis) |
|---|---|---|
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Thr-Lys-Pro-Arg-Pro-Gly-Pro |
| Origin-fragment | ACTH 4-7 (hormone fragment) | Tuftsin (immunopeptide) |
| Molecular weight | 813.94 g/mol | 751.88 g/mol |
| Primary research domain | Cognition · BDNF · neuroprotection · acute focus | Anxiolysis · mood balance · GABA/serotonin |
| BDNF upregulation hippocampus | Very strong (acute within 60 min) | Strong (chronic) |
| NGF upregulation | Strong | Moderate |
| Dopamine modulation | D2/D3 acute activation | D2-sensitivity balance |
| GABAergic modulation | Limited | Strong (indirect via enkephalin) |
| Serotonin system | Selective PFC modulation | SERT downregulation · 5-HT elevation |
| Acute focus response | Strong · attention boost within 30-60 min | Moderate (calm-clear profile) |
| Neuroprotection ischaemia | Very strong (stroke models) | Moderate |
| Catecholamine peak | Absent | Absent |
| Withdrawal/tachyphylaxis | None in chronic models | None |
| HPLC-purity Primal lot | ≥99% | ≥99% |
| Optimal research role | Cognitive performance research · acute focus | Mood-balance research · anti-stress |
The biochemical conclusion: Selank is the homeostatic rebalancer — it restores GABAergic tone, serotonin and neuropeptide balance to a calm-clear equilibrium. Semax is the neurotrophic accelerator — it acutely pushes BDNF, NGF and dopamine D2/D3 signaling upward for focus and neuroprotection. Both are complementary, not substitutes. In configuration models, Selank+Semax is often positioned as the "calm focus" Russian heptapeptide research protocol — Selank dampens stress tone, Semax amplifies cognitive drive.
The Molecular Mechanics
At the level of central nervous system cultures and in-vivo behavioural models, the following effects of Semax have been documented:
- BDNF expression acutely elevated in hippocampus and frontal cortex within 30-60 min post-exposure in animal models
- NGF (Nerve Growth Factor) chronically upregulated → synaptic density and dendritic arborisation enhanced
- TrkB receptor signaling (downstream of BDNF) persistently activated → CREB phosphorylation and memory consolidation
- CaMKII and CREB pathway activation → late-LTP (long-term potentiation) enhanced
- Improved memory performance in Morris water maze and passive avoidance test models
- No receptor downregulation in chronic exposure in chronic in-vitro models — unique for BDNF-modulating research compounds
For research into acute focus, attention and motivation circuits, Semax delivers a unique non-stimulant profile:
- Acute dopamine D2-receptor activation in striatum and prefrontal cortex without catecholamine release
- D3-receptor selective modulation → focus + motivation without hyperactivity markers
- Elevated attention in attention-task models without ataxia or motor unrest
- No catecholamine peak (norepinephrine and epinephrine baselines unchanged) → no cardiovascular pressure
- No post-stimulant crash in chronic exposure — unique for focus-modulating peptide research
- Synergy with selective attention research models (working memory tasks, executive function tests)
The most unique Semax property is measurable neuroprotection in ischaemic and cerebral hypoxia research models — a research domain where classical nootropics do not reach:
- Reduced infarct zone in middle cerebral artery occlusion (MCAO) models in rat and mouse studies
- Improved neuronal survival rate in penumbra zones surrounding ischaemic tissue
- Anti-apoptotic response (reduced caspase-3 activation, elevated Bcl-2 expression)
- Microglia activation dampened → reduced TNF-α, IL-6, IL-1β in chronic neuro-inflammation cultures
- Cerebral perfusion supported in cerebrovascular research models
- Russian clinical research dossier for stroke recovery (research reference only, no human claim) demonstrates reproducibility
The Primal Peptides Standard
Every batch is independently validated. The Certificate of Analysis (COA) is the binding source of truth for each lot — publicly available, batch-specific and generated by an independent third-party laboratory prior to dispatch. We publish no claims not per-lot substantiated by the COA.
- 01RP-HPLC with UV detection → purity ≥ 98–99%
- 02Mass spectrometry → molecular weight confirmation
- 03Janoshik 3rd-party verification → public COA per lot
Our validation architecture is deliberately minimalist and strict: three reproducible assays, one independent verification, one public certificate. For the complete analytical dossier of your specific batch, consult the COA with your shipment or via our public verification page.
Semax activates dopamine D2/D3 circuits and acutely modulates BDNF/NGF. Research protocols must strictly control catecholamine baselines, attention-task baselines and any co-administration with other CNS- active research compounds (dopamine modulators, MAO inhibitors) in animal models. Acute focus response may appear within 30-60 min — design test timing accordingly.
Legal disclaimer: Semax is exclusively intended for IN-VITRO RESEARCH. Not for human use. Not for consumption. Not for nasal or oral application.
Conclusion — The architect of mental energy
Semax is not just another nootropic. It is a dedicated cognitive accelerator that acutely activates BDNF, NGF and dopamine D2/D3 signaling via neurotrophic pathway modulation — without catecholamine peak, without cardiovascular pressure, without post-stimulant crash. For researchers who wish to study acute focus, neuroprotection and BDNF-mediated synaptic plasticity in a molecularly targeted manner, Semax is the missing heptapeptide instrument.
Activation over agitation. Drive over depletion. Neurotrophic over stimulant.
Semax
Referenzstandard direkt aus dem Primal Peptides EU Labor – vakuumversiegelt, anonymisiert und diskret innerhalb der EU versandt. Strikte –20 °C Lagerungsprotokolle vor Versand garantieren Lot-Integrität.
NUR FÜR IN-VITRO-FORSCHUNG · NICHT FÜR DEN MENSCHLICHEN GEBRAUCH · GMP-KONFORME SYNTHESE